journal article·2023-11Open access

FBXO7 Confers Mesenchymal Properties and Chemoresistance in Glioblastoma by Controlling Rbfox2‐Mediated Alternative Splicing

Shangbiao Li, Yanwen Chen, Yuxin Xie, Hongchao Zhan, Yu Zeng, Kunlin Zeng, Li Wang, Ziling Zhan, Cuiying Li, Liqian Zhao, Xiaoxia Chen, Yujing Tan, Zhongyong Wang, Junguo Bu, Ye Song, Fan Deng, Aidong Zhou

Advanced Science· Volume 10· Issue 33

Abstract

Abstract Mesenchymal glioblastoma (GBM) is highly resistant to radio‐and chemotherapy and correlates with worse survival outcomes in GBM patients; however, the underlying mechanism determining the mesenchymal phenotype remains largely unclear. Herein, it is revealed that FBXO7, a substrate‐recognition component of the SCF complex implicated in the pathogenesis of Parkinson's disease, confers mesenchymal properties and chemoresistance in GBM by controlling Rbfox2‐mediated alternative splicing. Specifically, FBXO7 ubiquitinates Rbfox2 Lys249 through K63‐linked ubiquitin chains upon arginine dimethylation at Arg341 and Arg441 by PRMT5, leading to Rbfox2 stabilization. FBXO7 controls Rbfox2‐mediated splicing of mesenchymal genes, including FoxM1, Mta1, and Postn. FBXO7‐induced exon Va inclusion of FoxM1 promotes FoxM1 phosphorylation by MEK1 and nuclear translocation, thereby upregulates CD44, CD9, and ID1 levels, resulting in GBM stem cell self‐renewal and mesenchymal transformation. Moreover, FBXO7 is stabilized by temozolomide, and FBXO7 depletion sensitizes tumor xenografts in mice to chemotherapy. The findings demonstrate that the FBXO7‐Rbfox2 axis‐mediated splicing contributes to mesenchymal transformation and tumorigenesis, and targeting FBXO7 represents a potential strategy for GBM treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA modifications and cancer · Autophagy in Disease and Therapy · Cancer-related gene regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Radiation Oncology Zhujiang Hospital Southern Medical University Guangzhou 510280 China

Department of Cell Biology School of Basic Medical Science Southern Medical University Guangzhou 510515 China

Department of Neurosurgery Nanfang Hospital Southern Medical University Guangzhou 510515 China

Department of Neurosurgery The Second Affiliated Hospital of Soochow University Suzhou 215004 China

Guangdong Province Key Laboratory of Molecular Tumor Pathology Southern Medical University Guangzhou 510515 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Guangdong Province

References (45)

Show source-provided references
1. 10.1016/j.trecan.2020.01.00910.1016/j.trecan.2020.01.009 ↗
2. 10.1038/ncb339610.1038/ncb3396 ↗
3. 10.1016/j.ccell.2017.02.01310.1016/j.ccell.2017.02.013 ↗
4. 10.1002/advs.20200201510.1002/advs.202002015 ↗
5. 10.1093/brain/awz04410.1093/brain/awz044 ↗
6. 10.1038/nrm358210.1038/nrm3582 ↗
7. 10.15252/embj.20159358510.15252/embj.201593585 ↗
8. 10.1371/journal.pone.001698310.1371/journal.pone.0016983 ↗
9. 10.1212/01.wnl.0000338144.10967.2b10.1212/01.wnl.0000338144.10967.2b ↗
10. 10.1038/nn.348910.1038/nn.3489 ↗
11. 10.1038/cdd.2017.17510.1038/cdd.2017.175 ↗
12. 10.1038/sj.emboj.760077510.1038/sj.emboj.7600775 ↗
13. 10.1093/hmg/ddab33010.1093/hmg/ddab330 ↗
14. 10.1038/nrc315010.1038/nrc3150 ↗
15. 10.3389/fneur.2020.0089810.3389/fneur.2020.00898 ↗
16. 10.1038/ng.49110.1038/ng.491 ↗
17. 10.1038/s41388-020-01543-110.1038/s41388-020-01543-1 ↗
18. 10.1016/j.ccell.2016.05.00210.1016/j.ccell.2016.05.002 ↗
19. 10.1186/s13041-016-0218-210.1186/s13041-016-0218-2 ↗
20. 10.1016/j.molcel.2022.01.02210.1016/j.molcel.2022.01.022 ↗
21. 10.1038/s41556-021-00732-810.1038/s41556-021-00732-8 ↗
22. 10.1038/s41467-018-04620-y10.1038/s41467-018-04620-y ↗
23. 10.1158/0008-5472.CAN-20-187110.1158/0008-5472.CAN-20-1871 ↗
24. 10.1016/j.cell.2017.06.02210.1016/j.cell.2017.06.022 ↗
25. 10.1016/j.molcel.2014.06.03510.1016/j.molcel.2014.06.035 ↗
26. 10.1101/gad.182477.11110.1101/gad.182477.111 ↗
27. 10.1038/ncb309010.1038/ncb3090 ↗
28. 10.3389/fonc.2020.62683610.3389/fonc.2020.626836 ↗
29. 10.1038/onc.2015.28210.1038/onc.2015.282 ↗
30. 10.1016/j.ccr.2011.10.00110.1016/j.ccr.2011.10.001 ↗
31. 10.1002/mc.2244310.1002/mc.22443 ↗
32. 10.1038/cdd.2014.3110.1038/cdd.2014.31 ↗
33. 10.1016/j.ccr.2013.08.00110.1016/j.ccr.2013.08.001 ↗
34. 10.1007/s00018-014-1665-510.1007/s00018-014-1665-5 ↗
35. 10.1016/j.bbrc.2020.08.09810.1016/j.bbrc.2020.08.098 ↗
36. 10.1038/s41467-017-01366-x10.1038/s41467-017-01366-x ↗
37. 10.1002/advs.20200485210.1002/advs.202004852 ↗
38. 10.1038/s41388-018-0655-810.1038/s41388-018-0655-8 ↗
39. 10.1038/onc.2013.5010.1038/onc.2013.50 ↗
40. 10.1016/j.ccell.2019.07.00310.1016/j.ccell.2019.07.003 ↗
41. 10.1016/j.molcel.2016.11.00310.1016/j.molcel.2016.11.003 ↗
42. 10.1016/j.cell.2021.05.03810.1016/j.cell.2021.05.038 ↗
43. 10.1038/s41467-021-21204-510.1038/s41467-021-21204-5 ↗
44. 10.1093/hmg/ddv34010.1093/hmg/ddv340 ↗
45. 10.18632/aging.20223610.18632/aging.202236 ↗